Inflammation markers and incident venous thromboembolism: The REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 12, 2014, Pages 1993-2001

  Olson, N C ^a   Cushman, M ^a   Lutsey, P L ^b   Mcclure, L A ^c   Judd, S ^c   Tracy, R P ^a   Folsom, A R ^b   Zakai, N A ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biomarkers; C reactive protein; Inflammation; Serum albumin; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN; SERUM ALBUMIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY MASS; BOOTSTRAPPING; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK FACTOR; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM; BLOOD; ETHNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84916641682     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12742     Document Type: Article

References (45)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
2. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149: 824-33.
3. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362-5.
4. Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association? Clin Chem Lab Med 2010; 48: 1693-701.
5. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-30.
6. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26-34.
7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
8. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-19.
9. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010; 30: 1672-8.
10. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
11. Vormittag R, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C, Hirschl M, Pabinger I. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost 2005; 93: 488-93.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
13. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-42.
14. Hald EM, Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Brox J, Hansen JB. High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study. Haematologica 2011; 96: 1189-94.
15. van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000; 83: 536-9.
16. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004; 2: 619-22.
17. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 2006; 3: e334.
18. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005; 25: 135-43.
19. Wojcik NC, Huebner WW, Jorgensen G. Strategies for using the National Death Index and the Social Security Administration for death ascertainment in large occupational cohort mortality studies. Am J Epidemiol 2010; 172: 469-77.
20. Zakai NA, McClure LA, Judd SE, Safford MM, Folsom AR, Lutsey PL, Cushman M. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation 2014; 129: 1502-9.
21. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997; 54: 201-8.
22. Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL, van der Meer J. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301: 1790-7.
23. van Schouwenburg IM, Mahmoodi BK, Veeger NJ, Kluin-Nelemans HC, Gansevoort RT, Meijer K. Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol 2012; 156: 667-71.
24. Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010; 104: 100-4.
25. Barbano B, Gigante A, Amoroso A, Cianci R. Thrombosis in nephrotic syndrome. Semin Thromb Hemost 2013; 39: 469-76.
26. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 2012; 7: 43-51.
27. Warnock DG, Muntner P, McCullough PA, Zhang X, McClure LA, Zakai N, Cushman M, Newsome BB, Kewalramani R, Steffes MW, Howard G, McClellan WM. Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010; 56: 861-71.
28. Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. J Thromb Haemost 2013; 11: 634-41.
29. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2: 2156-61.
30. Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126: 113-18.
31. Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, Steger G, Jaeger U, Zielinski C, Pabinger I. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8: 114-20.
32. Trujillo-Santos J, Di Micco P, Iannuzzo M, Lecumberri R, Guijarro R, Madridano O, Monreal M. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 905-11.
33. van der Bom JG, Heckbert SR, Lumley T, Holmes CE, Cushman M, Folsom AR, Rosendaal FR, Psaty BM. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 2009; 7: 399-405.
34. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
35. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-16.
36. Speidl WS, Zeiner A, Nikfardjam M, Geppert A, Jordanova N, Niessner A, Zorn G, Maurer G, Schreiber W, Wojta J, Huber K. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J Am Coll Cardiol 2005; 45: 30-4.
37. Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Juhan-Vague I, Alessi MC, Tiret L, Lathrop M, Emmerich J, Morange PE. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009; 113: 5298-303.
38. Vormittag R, Funk M, Mannhalter C, Schonauer V, Vukovich T, Minar E, Bialonczyk C, Hirschl M, Pabinger I. C-reactive protein 3′ UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis 2006; 188: 406-11.
39. Morange PE, Bezemer I, Saut N, Bare L, Burgos G, Brocheton J, Durand H, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Germain M, Nicaud V, Heath S, Ninio E, Delluc A, Munzel T, Zeller T, et al. A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. Am J Hum Genet 2010; 86: 592-5.
40. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10: 136-44.
41. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Kollnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-35.
42. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Kollnberger M, Wakefield TW, Lammle B, Massberg S, Wagner DD. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 2011; 117: 1400-7.
43. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
44. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-61.
45. Adams NB, Lutsey PL, Folsom AR, Herrington DH, Sibley CT, Zakai NA, Ades S, Burke GL, Cushman M. Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost 2013; 11: 1078-84.